Push launch MHRA approves GLP –1 receptor agonist semaglutide to lower risk of great heart problems in obese or overweight Grownups Semaglutide is the main weightloss drug accredited in the united kingdom like a preventative therapy for those with founded cardiovascular diseaseObserve patients thoroughly for signs and signs of acute pancreatitis